A Closer Look: Trends and Challenges in Spinal Muscular Atrophy Treatment Market

The spinal muscular atrophy medicine market was estimated at USD 1.26 billion in 2022 and is likely to grow at a CAGR of 13.44% during 2023-2028 to reach USD 2.68 billion in 2028.

Spinal Muscular Atrophy (SMA) is a very rare genetic disorder that affects the part of the central nervous system that controls voluntary muscle movements. SMA is an autosomal recessive neurodegenerative genetic disorder that is characterized by atrophy and the weakening of muscles. It is one of the most common debilitating genetic disorders and a primary genetic cause of death among infants. It mainly affects approximately one in 10,000 live births across the globe.